DIRS.INFO The most relevant business & tech news

☆ Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products beat expectations. Leqembi, which Biogen shares with Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. last summer. That's above the $31 million analysts had expected, according to estimates compiled by StreetAccount. Tecfidera, for example, booked $252.2 million in revenue in the second quarter, which is relatively flat from the year-earlier period. Analysts had expected the once-blockbuster drug to rake in $233.3 million in revenue for the quarter, according to StreetAccount.

Persons: Biogen, StreetAccount, Leqembi, Drug Administration greenlit Skyclarys, Biogen's Organizations: Eisai, LSEG, Reata Pharmaceuticals, Drug Administration, Sage Therapeutics Locations: U.S, Europe

☆ Amazon has discussed a 'DoctorAI' tool to automate routine healthcare tasks
▼ + stars: | 2024-07-31 | by ( Eugene Kim | ) www.businessinsider.com time to read: +5 min

Read previewAmazon's One Medical team has discussed building a new large language model called "DoctorAI" to automate routine healthcare tasks, according to an internal planning document obtained by Business Insider. In one section, the One Medical team discusses their most disruptive ideas, and this is where the new AI tool was proposed. Big foundation models are often used as a starting point to develop more focused, specialized AI models and tools. "We do not use our customers' protected health information to train our current health AI models, and to imply we do would be incorrect." It also hoped to handle 87,000 customer service contacts in 2024 through "additional self-service content and the AI healthcare assistant service," the document stated.

Persons: —, Andy Jassy, Rohit Prasad, Sunita Mishra Organizations: Service, Business, Amazon Pharmacy, Olympus, Microsoft, Google, Amazon, Amazon Web Services

☆ GEHC gives reasons to look beyond temporary China woes and shares reverse higher
▼ + stars: | 2024-07-31 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. Organic revenue growth was 1%. We saw a continued acceleration of Vizamyl doses delivered in the U.S. in the second quarter. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years." As a result, we're lowering our total company full-year organic revenue growth guidance."

Persons: Philips, It's, Eli Lilly, GEHC, —, Jay Saccaro, We're, Arduini, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: GE Healthcare, Management, Revenue, LSEG, General Electric, Philips, Siemens, Club, GE Healthcare YTD, GE Healthcare's, Care Solutions, Pharmaceutical Diagnostics, U.S, CNBC, Lightrocket, Getty Locations: China, Eisai, U.S

☆ Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The newly FDA approved Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai. The study results on Leqembi, which Eisai shares with Biogen , also found that a patient's Alzheimer's disease worsens after they stop treatment. The results are a first glimpse at what Alzheimer's patients' future could look like on therapies such as Leqembi, which is currently taken twice a month through an infusion. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S.

Persons: Lynn Kramer, Leqembi, Eisai, Kramer Organizations: FDA, Abington Neurological Associates, Biogen, CNBC, Alzheimer's Association International Conference, Alzheimer's Association Locations: Abington, Abington , PA, U.S, Philadelphia

☆ Alzheimer’s blood test catches 90% of early dementia cases, study finds
▼ + stars: | 2024-07-28 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +10 min

CNN —A combined blood test for cognitive decline has a 90% accuracy rate in determining whether memory loss is due to Alzheimer’s disease, a new study found. “The p-tau217 blood test is turning out to be the most specific for Alzheimer’s and the one with the most validity. “These are absolutely transformational times.”How does a p-tau217 blood test work? The results of the blood tests were then measured against patient diagnoses provided by Swedish primary care doctors and specialists. “There’s no one more bullish on these tests than I am, but Alzheimer’s blood tests aren’t fully definitive yet,” he said.

Persons: CNN —, Sebastian Palmqvist, ” Palmqvist, ”, Maria Carrillo, Carrillo, “ You’re, that’s, ” Carrillo, “, ” Tau tangles, Richard Isaacson, Oskar Hansson, ” Hansson, Hansson, Isaacson, ” Isaacson Organizations: CNN, Lund University, “, Alzheimer’s Association, International Conference Locations: Sweden, Alzheimer’s, Florida, United States, Philadelphia

☆ European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
▼ + stars: | 2024-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

European drug regulators on Friday rejected the Alzheimer's treatment Leqembi from Biogen and Eisai , creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. But it almost always follows the drug regulator's recommendations. The European Medicines Agency's human medicines committee recommended against granting marketing authorization for Leqembi. Leqembi and Kisunla are milestones in the treatment of Alzheimer's after three decades of failed efforts to develop medicines that can fight the fatal disease. In 2021, the European Medicines Agency rejected Aduhelm.

Persons: Eisai, Leqembi, Eli Lilly, Kisunla, Aduhelm Organizations: U.S, European Commission, U.S . Food, Drug Administration, Medicines, European Medicines Agency, Alzheimer's Locations: Biogen, U.S, Japan, South Korea, China, Israel, Europe, Alzheimer's Europe

☆ GE HealthCare taps Amazon Web Services to build generative AI for medical use
▼ + stars: | 2024-07-25 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +3 min

GE HealthCare on Thursday announced it is teaming up with Amazon Web Services to build new generative artificial intelligence models and tools that can efficiently analyze complex medical data. GE HealthCare, which offers medical imaging, ultrasound, patient care and pharmaceutical diagnostic solutions, believes generative AI can help. GE HealthCare offers its own AI tools, but its partnership with AWS will supply the company with the technical infrastructure required to quickly build generative AI models and tools at scale. GE HealthCare will use AWS' solutions like Amazon Bedrock and Amazon SageMaker, according to a release Thursday. Kass-Hout said GE HealthCare maintains rigorous testing and standards before bringing products to market, and the same will be true with the generative AI applications it develops.

Persons: Dr, Taha Kass, Kass, Hout, Matt Wood Organizations: GE, Amazon Web Services, Deloitte, GE HealthCare, AWS, CNBC

☆ Serena Williams's husband and Reddit cofounder says he was diagnosed with Lyme disease and is starting treatment
▼ + stars: | 2024-07-18 | by ( Julia Pugachevsky | ) www.businessinsider.com time to read: +3 min

Read previewOn Tuesday, Alexis Ohanian, a Reddit cofounder and Serena Williams' husband, announced on X that he was diagnosed with Lyme disease after getting a "full battery of health scans." Lyme diagnosis is tricky and expensiveDiagnosing Lyme disease is complicated. Treatment is complex and controversialGetting proper treatment for Lyme disease is important, as the long-term effects can range from severe arthritis and life-threatening heart complications. Because there's only one way to test for Lyme, treating chronic Lyme disease symptoms is complicated — and some doctors question if it's real at all. AdvertisementAbout 15% of people worldwide are affected by Lyme disease, yet treatment remains difficult.

Persons: —, Alexis Ohanian, Serena Williams, Lyme, — Alexis Ohanian 🇦🇲 ( Organizations: Service, Business

☆ Huma, a London-based healthcare startup, just raised $80 million to offer new AI services using this 11-slide pitch deck
▼ + stars: | 2024-07-16 | by ( Callum Burroughs | ) www.businessinsider.com time to read: +2 min

Read previewHuma, an AI digital healthcare company, has raised $80 million in Series D funding. "AI is core to how we build scalable digital health solutions," Huma CEO Dan Vahdat, told Business Insider. "It is a challenging environment for digital health companies in general, particularly with the public markets being down," Vahdat added. The company's $80 million Series D funding round was raised by new and existing investors such as AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer. Check out Huma's 11-slide Series D pitch deck below:

Persons: —, Dan Vahdat, Huma, Sifted, Vahdat Organizations: Service, Business, Bayer, AstraZeneca, Hat Technology, HAT, Hitachi Ventures Locations: Swedish

☆ Stocks making the biggest moves midday: Delta Air Lines, SoundHound AI, WD-40, Tesla and more
▼ + stars: | 2024-07-11 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

Check out the companies making headlines in midday trading: Delta Air Lines — The stock fell almost 5% after the airline issued a sales growth forecast for the third quarter that came in below expectations. The company also reported an almost 30% decrease in net income for the second quarter compared to a year ago. Shares of major airline stocks American Airlines and United Airlines also fell around 4.7% and 3.7%, respectively, following the results. WD-40 reported total net sales of $155 million in the fiscal third quarter, up 9% from the year-ago period. Semiconductor names — Investors took a few chips off the table on Thursday, selling high-flying semiconductor stocks.

Persons: QuantumScape, Conagra, Lantheus, Tesla, Horton, —, Alex Harring, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Tanaya Macheel, Darla Mercado Organizations: Delta Air Lines, American Airlines and United Airlines, Costco, Peugeot, Opel, Vauxhall, Lantheus Holdings, Medicare, Services, PepsiCo, Revenue, Bloomberg News, Bloomberg, Industries, Builders, Semiconductor, —, VanEck Semiconductor, Nvidia Locations: U.S, Canada, Europe

☆ Pressure is mounting on Biden to take a cognitive test. It could be a 'slippery slope' for future presidents, experts say.
▼ + stars: | 2024-07-09 | by ( Mikhaila Friel | ) www.businessinsider.com time to read: +5 min

Read previewJoe Biden is facing mounting pressure to prove he's medically fit to run for a second term, but experts say a cognitive test could set a dangerous precedent. Speaking on CBS's "Face the Nation," Sen. Lindsey Graham said all presidential nominees, including Biden and Trump, should take a cognitive test. Cognitive tests are usually quick and simple and can check for functions such as concentration, abstract thinking, language, and memory. He told ABC's Stephanopoulos on Friday: "I have a cognitive test every single day." According to White House press secretary Karine Jean-Pierre, after Biden's physical in February, his doctors decided he didn't need a cognitive test.

Persons: —, Joe Biden, Biden, Donald Trump, ABC's George Stephanopoulos, Sen, Lindsey Graham, Trump, Kevin O'Connor, Dr, Kenneth Boockvar, Biden hasn't, ABC's Stephanopoulos, Karine Jean, Pierre, Thomas, it's, Andrew Payne, I'm, Charan Ranganath, Payne Organizations: Service, Business, Reuters, Biden, Washington Post, Gerontology, Geriatrics, University of Alabama, White, University College London, Mensa, City University, University of California, BI Locations: Birmingham

☆ Dr. Sanjay Gupta: It’s time for President Biden to undergo detailed cognitive and neurological testing and share his results
▼ + stars: | 2024-07-05 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +10 min

Biden was examined by his physician after the debate to check on a cold, the White House said, but it was a “brief check” and not a physical. Biden and his aides have said it was a “bad night.” The White House press team said Biden had a cold but did not take any medications to treat symptoms. The White House has rejected requests from the press to release more medical records and question Biden’s physician, Dr. Kevin O’Connor. PoolWe often hear that observing a candidate on the campaign trail is the best assessment of the individual’s physical and cognitive health. Back in 2020, Biden said he was “constantly tested” by the work of running for president.

Persons: Joe Biden, Lewy, Biden, Karine Jean, Pierre, it’s “, Donald Trump, Trump’s, he’d, Trump, Bruce Aronwald, ” Trump, Jay Olshansky, Jean, Dr, Sanjay Gupta, “, Nancy Pelosi, Kevin O’Connor, Biden’s, O’Connor, Sen, John McCain —, —, John McCain, you’ve, ”, Amanda Sealy Organizations: CNN, United States, White, Trump, School of Public Health, University of Illinois, White House, Democratic, CNN Health Locations: Montreal, Chicago

☆ ARFID: the eating disorder you haven’t heard of
▼ + stars: | 2024-07-02 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +8 min

Now 8 years old, Hannah is being treated for Avoidant/Restrictive Food Intake Disorder, or ARFID. Unlike eating disorders like anorexia or bulimia nervosa, this diagnosis isn’t concerned with body shape or size, said Kate Dansie, clinical director of the Eating Disorder Center in Rockville, Maryland. Instead, people with ARFID are very limited in the foods they feel safe and comfortable eating, Dansie said. While an estimated 9% of the US population will have an eating disorder at some point, studies suggest that somewhere between 0.5% and 5% of the population has ARFID, according to the National Eating Disorders Association. One way to spot the difference is the level of impairment and anxiety that comes with facing a new food, Murray said.

Persons: Hannah, didn’t, Michelle, Kate Dansie, Dansie, “, ”, Stuart Murray, Murray, ARFID, nutritively, ” Hannah, ” Dansie, ” Murray, –, Nicole Stettler, “ It’s, ” Michelle Organizations: CNN, Girl Scouts, Disorders, Eating Disorders, University of Southern, “, Rogers Behavioral Health Locations: Rockville , Maryland, University of Southern California

☆ In new criteria for Alzheimer’s, some see much-needed progress while others fear profit may be driving ‘diagnostic creep’
▼ + stars: | 2024-07-01 | by ( Brenda Goodman | ) edition.cnn.com time to read: +12 min

CNN —With another pricey Alzheimer’s disease treatment expected to receive an approval decision soon, the nonprofit Alzheimer’s Association has published the final version of its new diagnostic criteria for the disease. Together with another protein, tau, which makes fibrous tangles that block the communication of nerve cells, they are considered a hallmark of Alzheimer’s disease. “There’s no evidence for it,” said Dr. George Perry, a neurobiologist and editor of the Journal of Alzheimer’s Disease. Two members of the panel were employees of the Alzheimer’s Association, which also takes funding from pharmaceutical companies. Widera says he hopes that in the next round of guidelines, the Alzheimer’s Association will consider the risks involved.

Persons: There’s, –, donanemab, “, ”, George Perry, Adriane Fugh, Berman, haven’t, Maria C, Carrillo, Alzheimer’s, It’s, Eric Widera, Widera, it’s, Aduhelm, Karl Herrup, Clifford Jack, ” Jack, “ It’s, Niles Franz, ” Franz, Dr, Sanjay Gupta, Franz, ” Widera Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, FDA, Georgetown University, University of California San, American Geriatrics Society, Abbott Labs, University of Pittsburgh School of Medicine, Mayo Clinic, Nature Medicine, federal National Institute, Aging, Alzheimer’s Association International, National Institute, National Institutes of Health, NIA, Alzheimer’s, National Academy of Medicine, CNN Health, Association Locations: University of California San Francisco

☆ Indian tycoon Ratan Tata appeals for blood donations for sick puppy
▼ + stars: | 2024-06-28 | by ( Lianne Kolirin | Aishwarya S. Iyer | ) edition.cnn.com time to read: +3 min

CNN —A super-rich Indian businessman took to social media to appeal for urgent blood donations for a critically ill puppy. Tata, who has 9.7 million Instagram followers, wrote: “I would really really appreciate your help. Ratan Tata has long been known for his concern for animals and set up a veterinary hospital in Mumbai earlier this year. Last year, the Press Trust of India estimated there were around 62 million stray dogs in the country, although experts say the real number would be nearly impossible to verify. In an Instagram post last year, he expressed concern for the safety of stray cats and dogs that shelter under cars during the monsoon season.

Persons: Ratan Tata, Instagram, Tata, “, ” Tata, Indranil Aditya, Leo, Scooby, Ronny, Ivan, Sandeep Palav, Tito, ” Organizations: CNN, Tata Group, Tata Motors, Rover, Ford, Animal Hospital, Tata, Bloomberg, Getty, Tata Trusts, Press Trust of India Locations: Mumbai, Animal Hospital Mumbai, Casper, German

☆ Embattled Alzheimer’s Researcher Is Charged With Fraud
▼ + stars: | 2024-06-28 | by ( Apoorva Mandavilli | More About Apoorva Mandavilli | ) www.nytimes.com time to read: 1 min

A scientist whose research has been at the center of controversy over an Alzheimer’s drug candidate has been charged with fraud. Dr. Wang’s studies underpinned research into a diagnostic test for Alzheimer’s disease and simufilam, a drug in advanced clinical trials. Simufilam’s manufacturer, Cassava Sciences, a pharmaceutical company based in Texas, has said the drug improves cognition in Alzheimer’s patients. Alzheimer’s disease affects roughly six million Americans — a number that is expected to double by 2050 — and promising treatments generate tremendous excitement. Cassava’s stock soared after each round of reported results from its trials.

Persons: Hoau, Yan Wang, — Organizations: City College of New, National Institutes of Health, Sciences Locations: City College of New York, Texas

☆ My internship at Bridgewater Associates felt like a 'Black Mirror' episode
▼ + stars: | 2024-06-23 | by ( Jane Zhang | ) www.businessinsider.com time to read: +11 min

The summer after my sophomore and junior years at Harvard University, I interned at Bridgewater Associates, the world's largest hedge fund. AdvertisementAnd while I definitely see parallels between my time at Bridgewater and that "Black Mirror" episode, I look back fondly on my time there. AdvertisementAuthenticity is a big thing at Bridgewater, so I went into the interview wanting to be completely myself. I worked on a lot of diversity initiatives, figuring out how to make Bridgewater more streamlined and accessible to employees. It helped shape who I am today, especially how I think about feedback, work, and the relationships I have at work.

Persons: Daria Rose, Ray, , I've, Ray Dalio, would've, She'd, Myers, —, we'd, I'd, It's, Dalio, it's, it'd, Ray Dalio isn't, We'd, Jane Zhang Organizations: Bridgewater Associates, Business, Harvard University, Bridgewater, Harvard, Briggs Locations: Ray Dalio's, Bridgewater, Westport , Connecticut, janezhang@businessinsider.com

One by one, each country with the money and the drive to compete started its own nuclear weapons program. Even with this kind of evidence in hand, science has reached only limited conclusions about how nuclear weapons testing affects individuals’ health. They helped create the 2021 Treaty on the Prohibition of Nuclear Weapons, signed by 93 countries, which bans the possession, use and testing of nuclear weapons. France has acknowledged its “debt” to Polynesians over nuclear testing, and it created a commission in 2010 to evaluate nuclear testing victim compensation claims, but it has never apologized. We are still wrestling with the damage wrought by testing nuclear weapons in our past.

Persons: —, Ernest Moniz, Barack Obama, ” Mr, Moniz, Trump, Trump’s, Biden, United States ’, Republic of Kiribati —, we’re, Robert Oppenheimer’s, Oppenheimer, Ben Wyatt, King Juda, Harry Truman, Oppenheimer’s, Karina Lester, ”, Willard F, Libby, Louis, couldn’t, Merril Eisenbud, Hinamoeura, Britain —, “, it’s, John Moody, Benetick Kabua Maddison, Maddison, Benetick, It’s, Vladimir Putin Organizations: Las, Washington, United States, Marshall, Embassy, D.C, Marshalls, U.S, Navy, United, Soviet Union, Britain, Atomic Energy Commission, St, Louis University, Washington University School of Dental Medicine, Bravo, U.S . Navy, Atomic Energy, Centers for Disease Control, Polynesia —, Nuclear Weapons, ., Pacific Mart, Educational, America Locations: U.S, Japan, United States, Russia, China, Nevada, Soviet Union, — Semipalatinsk, Kazakhstan, Reggane, Algeria, Montebello, Australia, Republic of Kiribati, Marshall Islands, Republic, Washington, Hiroshima, New Mexico, Las Vegas, Marshall, Hawaii, Philippines, Bikini, Atoll, Soviet, Africa, Polynesia, Xinjiang, The, Britain Britain, Britain, American, Kwajalein Atoll, France, France France, Tahiti, Nagasaki, Asia, Europe, India, Pakistan, North Korea, United, Kwajalein, Hawaii , California, Washington and Oregon, Arkansas, Springdale, you’re, Rhode Island, Moscow

☆ 6 types of depression identified in Stanford study
▼ + stars: | 2024-06-20 | by ( Kristen Rogers | ) edition.cnn.com time to read: +11 min

Some 30% to 40% of people with depression do not experience symptom improvement after trying one treatment, according to the study. And about 30% of people diagnosed with depression go on to experience treatment-resistant depression when the disorder doesn’t improve after multiple treatment attempts. Mapping depression in the brainThe authors used data from 801 adult participants who were previously diagnosed with depression or anxiety, and 137 healthy control group participants. The grant supports a five-year project involving 4,500 participants, which is centered on the development of a better diagnosis and treatment tool for depression biotypes. This method isn’t intended to replace or be the primary choice for assessments of individual cases of depression, Williams said.

Persons: biotypes, ”, Leanne Williams, Vincent V.C, Woo, Williams, Anhedonia, Jun Ma, Ma, Beth, George Vitoux, “, Richard Keefe, wasn’t, Keefe, Jonathan Alpert, Dorothy, Marty Silverman, Alpert, ” Keefe, you’re Organizations: Lifeline, CNN, Nature Medicine, Psychiatry, Behavioral Sciences, Stanford University School of Medicine, Stanford Center, Precision Mental Health, Wellness, Medicine, University of Illinois, Duke University Medical Center, Montefiore Medical, Albert Einstein College of Medicine, Psychiatric Association’s Council, Research, National Institute of Mental Health, National Institutes, Health’s, Mental Health Initiative Locations: California, United States, University of Illinois Chicago, North Carolina, New York City, Stanford

☆ Jim Cramer’s guide to investing: Too many gains can spell danger
▼ + stars: | 2024-06-18 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

To CNBC's Jim Cramer, there is such a thing as making too much money. "The best time to figure out if you're making too much money, meaning you're taking on a dangerous amount of risk, is during a big market-wide rally," he said. While admitting that he's not the most conservative investor, Cramer stressed that taking on too much risk is unwise. A portfolio that beats roaring averages can be another indicator that you're taking on needless risk, he said. "That will help you crush the averages in a rally, but it will also get you crushed by your losses in a sell-off.

Persons: Jim Cramer, Cramer, he's, That's

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ Apple jumps to a new high after AI unveil — plus, our latest thinking on 6 more portfolio stocks
▼ + stars: | 2024-06-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. "Notice where Stanley Black & Decker is when you have a good day for the bonds," Jim Cramer pointed out. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, you'll, Stanley Black, Decker, Dupont, Ed Breen, Jim, Eli Lilly, Eli Lilly Alzheimer's, Banks, Wells, Michael Santomassimo, Santomassimo, Morgan Chittum, We've, Tom Jorden, Coterra, Jorden, Jerome Powell, Jim Cramer's Organizations: CNBC, Longtime, Apple, Treasury, Club, DuPont, GE Healthcare, Huntington, Investing Club, Coterra Energy, Broadcom, VMware, Jim Cramer's Charitable

☆ Why AI deals in healthcare have grown faster than other areas of tech — and what VCs are paying close attention to
▼ + stars: | 2024-06-11 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +8 min

Healthcare AI companies raised $2.8 billion in the first quarter of this year, according to the SVB report titled "The AI-powered Healthcare Experience." SVB projects funding to AI healthcare companies to total $11.1 billion in 2024. While healthcare AI startups might have it better, they're not out of the woods. Healthcare startups using AI for administrative tasks have grabbed $6.6 billion since 2021 and made up 42% of healthcare AI deals in the first quarter of this year, according to SVB. AdvertisementIn some cases, Big Tech companies are pushing healthcare startups forward.

Persons: —, Raysa Bousleiman, they're, Siva Namasivayam, Galym, Bousleiman, Shiv Rao Abridge, Lynne Chou O'Keefe, Lightspeed's Imanbayev Organizations: Service, Silicon Valley Bank, Business, Big Tech, Abridge, Health, Lightspeed Venture Partners, Google, Fathom, Nvidia, Ventures, Technologies Locations: Cohere, Abridge, SVB .

☆ AI and the IPO market: Demand is there but product is lacking
▼ + stars: | 2024-06-10 | by ( Bob Pisani | ) www.cnbc.com time to read: +4 min

Tempus AI = AI in healthcare Tempus AI is seeking to sell 11 million shares at $35-$37 in its IPO and is slated to begin trading this Friday. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. AI IPOs: few and far between While AI is again the big investment theme of 2024, AI-themed IPOs have been few and far between. But the appetite for AI IPOs is large, and investors are scanning for new investments. Although the anticipated flood of AI IPOs has not yet materialized, Matt Kennedy is confident more are coming.

Persons: Matt Kennedy, Howe Ng, Ng, IPOs Organizations: Nasdaq, Astera Labs, Renaissance Capital, Nvidia, Cerebras Systems, Citigroup, Tempus, Forge Global Holdings

☆ Butterfly or Firefly: What’s Your Friendship Style?
▼ + stars: | 2024-06-09 | by ( Catherine Pearson | ) www.nytimes.com time to read: 1 min

Welcome to Well’s 5-day Friendship Challenge! Step one is to discover your friendship style. We all need social connection, but we thrive in different ways. Keep in mind that this is not a formal diagnostic, and none of friendship styles she defined in her book is better than the others. Still, these questions may help you better understand how you approach social interaction — and encourage you to stretch out of your comfort zone.

Persons: plumb, Kasley Killam

Search resuls for: "Diagnostic"

25 mentions found